Physician profile

Maryann E Martinovic

Plastic Surgery · Oklahoma City, OK

NPI 1528329133

$11,047.91

in general payments reported to CMS, 2019-2025

40 companies · $3,646 in 2025

The $3,646 reported for 2025 was more than what 90% of Plastic Surgery providers received nationally (typical 2025 total: $380).

See the full distribution for Plastic Surgery

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Consulting Fee$2,099.33
Food and Beverage$1,704.04
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program$1,200.00
Travel and Lodging$809.57
Honoraria$800.00
Gift$87.00

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Motiva USA, LLC $3,484.19 2024-2025
Rti Surgical, INC $2,000.00 2023-2024
Sientra, INC. $1,563.08 2020-2022
Bard Peripheral Vascular, INC. $738.32 2021
Tepha INC $691.78 2019-2020
Davol INC. $326.71 2022
Allergan, INC. $309.02 2019-2022
Tela Bio, INC. $229.23 2020-2023 Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex)
Abbvie INC. $229.00 2023-2025
Merck Sharp & Dohme LLC $156.45 2023-2025 Keytruda, Lynparza, Lenvima
Mentor Worldwide LLC $151.89 2020-2024 Mentor Memorygel Resterilizable Gel Sizer, Artoura Breast Tissue Expander
Eisai INC. $138.68 2023-2025
Astrazeneca Pharmaceuticals LP $104.93 2020-2024 Imfinzi, Lynparza
Janssen Biotech, INC. $102.65 2019-2023 Darzalex, Carvykti, Tecvayli
Seagen INC. $79.82 2019-2023 Adcetris
Show all 40 companies
CompanyGeneral paymentsYearsTop products
Myriad Genetic Laboratories, INC. $68.69 2021-2023 Myrisk
Acera Surgical, INC. $67.29 2022-2024 Restrata Wound Matrix
Amgen INC. $62.28 2022-2023 Blincyto, Nplate, Vectibix
Lilly USA, LLC $59.83 2022-2024 Retevmo
Genzyme Corporation $50.56 2019-2023
Medline Industries LP $41.57 2019
Genmab U.S., INC. $36.48 2023 Tivdak
Celgene Corporation $33.86 2019
Polynovo North America LLC $30.55 2024 Novosorb Btm
Smith+Nephew, INC. $26.98 2019-2020
Takeda Pharmaceuticals U.S.A., INC. $24.32 2019-2020
Ipsen Biopharmaceuticals, INC $24.13 2019
Medtronic USA, INC. $22.98 2019
Apyx Medical Corporation $22.49 2019
Morphosys, US INC. $20.33 2023 Monjuvi
Sobi, INC $18.78 2023
Mirati Therapeutics, INC. $18.07 2023 Krazati
Kci USA, INC. $17.25 2019
Fortovia Therapeutics, INC. $16.34 2019
Incyte Corporation $15.70 2023 Monjuvi
Regeneron Healthcare Solutions, INC. $14.71 2023 Libtayo
Puma Biotechnology, INC. $13.81 2023
Taiho Oncology, INC. $13.24 2021
Bioptics, INC. $11.73 2019
Rigel Pharmaceuticals, INC. $10.19 2023 Tavalisse, Rezlidhia

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Maryann E Martinovic

$11,047.91

in general payments reported 2019-2025

Years
2019-2025
Top company
Motiva USA, LLC
Context
The $3,646 reported for 2025 was more than what 90% of Plastic Surgery providers received nationally (typical 2025 total: $380).

https://glasscript.com/doctor/24265/maryann-e-martinovic

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.